Defense Secretary Asked To Brief US Congress On Pharmaceutical Supply Chain Security
Congress seeks advice from Defense Department on procuring active pharmaceutical ingredients domestically for national security purposes as efforts to identify areas of concern get underway.
You may also be interested in...
Monthly data are expected in annual reports on listed drugs and active ingredients from every registered site, starting in February.
US agency ensures pharmaceutical companies could manufacture critical medicines domestically even if cut off from China's API suppliers, while stockpiling pandemic medicines during pandemic with Baxter, Fresenius contracts.
Draft guidance on redundancy risk management plans layers risk-based expectations over new statutory requirements to plan more resilient supply chains for critical drugs.